Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death

Carlo Visco, Maria C Tisi, Andrea Evangelista, Alice Di Rocco, Anna-Katharina Zoellner, Vittorio R Zilioli, Stefan Hohaus, Roberta Sciarra, Alessandro Re, Cristina Tecchio, Annalisa Chiappella, Lucia Morello, Guido Gini, Luca Nassi, Tommasina Perrone, Anna L Molinari, Alberto Fabbri, Maria C Cox, Erica Finolezzi, Simone FerreroBenedetta Puccini, Isabel Alvarez De Celis, Annalisa Arcari, Dario Marino, Michele Merli, Francesco Piazza, Massimo Gentile, Matteo Pelosini, Giacomo Loseto, Olivier Hermine, Martin Dreyling, Marco Ruggeri, Maurizio Martelli, Eva Hoster, Umberto Vitolo, Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)940-944
Number of pages5
JournalBritish Journal of Haematology
Volume185
Issue number5
DOIs
Publication statusPublished - Jun 2019

Keywords

  • allogeneic transplant
  • cytarabine
  • mantle cell lymphoma
  • prognosis
  • refractory

Cite this

Visco, C., Tisi, M. C., Evangelista, A., Di Rocco, A., Zoellner, A-K., Zilioli, V. R., Hohaus, S., Sciarra, R., Re, A., Tecchio, C., Chiappella, A., Morello, L., Gini, G., Nassi, L., Perrone, T., Molinari, A. L., Fabbri, A., Cox, M. C., Finolezzi, E., ... Network, F. I. L. A. T. M. C. L. (2019). Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. British Journal of Haematology, 185(5), 940-944. https://doi.org/10.1111/bjh.15643